Print

Inotek Pharmaceuticals Corporation Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at Association for Research in Vision & Ophthalmology  
5/6/2009 9:11:12 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals today presented positive preclinical results supporting the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875. INO-8875 is a highly selective adenosine-1 (A1) receptor agonist in development as a topical agent for the treatment of elevated intraocular pressure (IOP) associated with primary open angle glaucoma and ocular hypertension. Elevated IOP can be a risk factor in the development and progression of optic nerve changes and vision loss associated with glaucoma and is thought to be a causal factor in the neuropathology of the disease. Results from preclinical studies of INO-8875 were presented in a poster presentation at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2009 Annual Meeting in Fort Lauderdale, FL.
//-->